Nuclear Engineering and Technology

Korean Nuclear Society (한국원자력학회)
권호 표지
DOI QR코드

DOI QR Code

Radiation dosimetry of 89Zr labeled antibody estimated using the MIRD method and MCNP code

  • Saeideh Izadi Yazdi (Medical Radiation Engineering Department, Science and Research Branch, Islamic Azad University) ;
  • Mahdi Sadeghi (Medical Physics Department, School of Medicine, Iran University of Medical Sciences) ;
  • Elham Saeedzadeh (Medical Radiation Engineering Department, Science and Research Branch, Islamic Azad University) ;
  • Mostafa Jalilifar (Medical Physics Department, School of Medicine, Iran University of Medical Sciences)
  • Received : 2022.08.01
  • Accepted : 2022.12.28
  • Published : 2023.04.25
Download PDF
⟨ Previous Next ⟩

Abstract

One important issue in using radiopharmaceuticals as therapeutic and imaging agents is predicting different organ absorbed dose following their injection. The present study aims at extrapolating dosimetry estimates to a female phantom from the animal data of 89Zr radionuclide accumulation using the Sparks-Idogan relationship. The absorbed dose of 89Zr radionuclide in different organs of the human body was calculated based on its distribution data in mice using both MIRD method and the MCNP simulation code. In this study, breasts, liver, heart wall, stomach, kidneys, lungs and spleen were considered as source and target organs. The highest and the lowest absorbed doses were respectively delivered to the liver (4.00E-02 and 3.43E-02 mGy/MBq) and the stomach (1.83E-03 and 1.66E-03 mGy/MBq). Moreover, there was a good agreement between the results obtained from both MIRD and MCNP methods. Therefore, according to the dosimetry results, [89Zr] DFO-CR011-PET/CT seems to be a suitable for diagnostic imaging of the breast anomalies for CDX-011 targeting gpNMB in patients with TNBC in the future.

Keywords

Acknowledgement

This research was supported by grant No. [14388] from the School of Medicine, Iran University of Medical Sciences (IUMS).

References

  1. A.A. Rose, et al., Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer, Clin. Cancer Res. 16 (7) (2010) 2147-2156.  https://doi.org/10.1158/1078-0432.CCR-09-1611
  2. A.A. Rose, et al., Osteoactivin promotes breast cancer metastasis to bone, Mol. Cancer Res. 5 (10) (2007) 1001-1014.  https://doi.org/10.1158/1541-7786.MCR-07-0119
  3. G. Maric, et al., Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer, Onco Targets Ther 6 (2013) 839-852, https://doi.org/10.2147/OTT. Epub 2013/07/23. 
  4. D.A. Yardley, et al., EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer, J. Clin. Oncol. 33 (14) (2015) 1609-1619.  https://doi.org/10.1200/JCO.2014.56.2959
  5. P.A. Ott, et al., Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma, J. Clin. Oncol. 32 (32) (2014) 3659. 
  6. V.A. Pollack, et al., Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB, Cancer Chemother. Pharmacol. 60 (3) (2007) 423-435.  https://doi.org/10.1007/s00280-007-0490-z
  7. X. Qian, et al., Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate, Molecular oncology 2 (1) (2008) 81-93.  https://doi.org/10.1016/j.molonc.2008.02.002
  8. R. Hernandez, et al., ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836, J. Contr. Release 264 (2017) 160-168.  https://doi.org/10.1016/j.jconrel.2017.08.029
  9. B.V. Marquez-Nostra, et al., Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent, Oncotarget 8 (61) (2017), 104303. 
  10. W.E. Bolch, et al., MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature, J. Nucl. Med. 50 (3) (2009) 477-484.  https://doi.org/10.2967/jnumed.108.056036
  11. A. Khorrami Moghaddam, et al., Determination of human absorbed dose of 201Tl (III)-DTPA-HIgG based on biodistribution data in rats, Radiat. Protect. Dosim. 141 (3) (2010) 269-274.  https://doi.org/10.1093/rpd/ncq172
  12. R. Sparks, B. Aydogan, Comparison of the Effectiveness of Some Common Animal Data Scaling Techniques in Estimating Human Radiation Dose, Oak Ridge Associated Universities, TN (United States), 1999. 
  13. S. Mattsson, L. Johansson, J. Liniecki, Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53. ICRP publication 106. Approved by the commission in October 2007, Ann. ICRP 38 (1-2) (2008) 1-197.  https://doi.org/10.1016/j.icrp.2009.04.001
  14. R. Laforest, et al., (89) Zr] Trastuzumab: Evaluation of radiation dosimetry, safety, and optimal imaging parameters in women with HER2-positive breast cancer, Mol. Imaging Biol. 18 (2016) 952-959 ([CrossRef. CrossRef][Google Scholar]).  https://doi.org/10.1007/s11307-016-0951-z
  15. S. Shanehsazzadeh, et al., Estimation of human effective absorbed dose of 67Ga-cDTPA-gonadorelin based on biodistribution rat data, Nucl. Med. Commun. 32 (1) (2011) 37-43.  https://doi.org/10.1097/MNM.0b013e328340b916
  16. M. Naserpour, S. Mohammadi, S.P. Shirmardi, Estimation of human absorbed dose of 99mTc-MAA using MIRD method based on animal data and comparison with MCNP simulation code, Arch.Adv. Biosci. 12 (1) (2021) 1-6. 
  17. M.A. Deri, et al., PET imaging with 89Zr: from radiochemistry to the clinic, Nucl. Med. Biol. 40 (1) (2013) 3-14.  https://doi.org/10.1016/j.nucmedbio.2012.08.004
  18. Y. Janjigian, et al., Positron emission tomography (PET) with 89Zr-labeled trastuzumab (89Zr-trastuzumab): Monitoring HER2 expression in HER2-positive gastric cancer in vivo, J. Clin. Oncol. 29 (4_suppl) (2011) 35. -35.